Appendix Table C28Asthma outcomes–oral selective antihistamine versus leukotriene receptor antagonist

Author, yearDrug, Dose/DayNaTime, weeksOutcomeMean BaselineEnd of treatmentMean Change from BaselineP
Baena-Cagnani, 2003Desloratadine 5mg3112Triamcinolone acetonide SS5.17-1.17NS
Montelukast 10mg3115.11-1.26
Baena-Cagnani, 2003Desloratadine 5mg3112Rescue medication useb-13.90.134
Montelukast 10mg311-16.3
Baena-Cagnani, 2003Desloratadine 5mg3114Triamcinolone acetonide SS-1.36NS
Montelukast 10mg311-1.52
Baena-Cagnani, 2003Desloratadine 5mg3114Rescue medication useb-12.10.078
Montelukast 10mg311-15.9
Baena-Cagnani, 2003Desloratadine 5mg3114Cough1.64-0.48cNS
Montelukast 10mg3111.61-0.50c
Baena-Cagnani, 2003Desloratadine 5mg3114Wheeze1.70-0.53cNS
Montelukast 10mg3111.71-0.57c
Baena-Cagnani, 2003Desloratadine 5mg3114Difficulty breathing1.82-0.56cNS
Montelukast 10mg3111.80-0.62c
Baena-Cagnani, 2003Desloratadine 5mg96d4FEV1d2.55-0.15NS
Montelukast 10mg101d2.55-0.18

FEV1 = Forced expired volume in 1 second; NS= non-significant; TA = Triamcinolone acetonide; TASS = total asthma symptom score.


Only patients analyzed reported.


Change in number of puffs of B-agonist use.


Values extracted from figures using Engauge Digitizer software.


In patients with baseline FEV1 <80%.

From: Appendix C, Evidence Tables

Cover of Treatments for Seasonal Allergic Rhinitis
Treatments for Seasonal Allergic Rhinitis [Internet].
Comparative Effectiveness Reviews, No. 120.
Glacy J, Putnam K, Godfrey S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.